COGT Cogent Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COGT

Price (delayed)

$11.23

Market cap

$796.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.31

Enterprise value

$654.24M

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed ...

Highlights
The company's equity rose by 19% YoY but it fell by 13% QoQ
Cogent Biosciences's quick ratio has increased by 8% from the previous quarter but it has decreased by 2.5% YoY
The company's net income has shrunk by 63% YoY and by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OCUP

Key stats

What are the main financial stats of COGT
Market
Shares outstanding
70.95M
Market cap
$796.73M
Enterprise value
$654.24M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$148.19M
EBITDA
-$141.66M
Free cash flow
-$137.35M
Per share
EPS
-$2.31
Free cash flow per share
-$1.94
Book value per share
$3.2
Revenue per share
$0
TBVPS
$3.72
Balance sheet
Total assets
$263.2M
Total liabilities
$39.64M
Debt
$19.46M
Equity
$223.56M
Working capital
$205.15M
Liquidity
Debt to equity
0.09
Current ratio
10.71
Quick ratio
10.49
Net debt/EBITDA
1.01
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-47%
Return on equity
-54.5%
Return on invested capital
-124%
Return on capital employed
-61.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COGT stock price

How has the Cogent Biosciences stock price performed over time
Intraday
0.27%
1 week
0.18%
1 month
4.17%
1 year
125.96%
YTD
-2.85%
QTD
4.08%

Financial performance

How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$159.66M
Net income
-$148.19M
Gross margin
N/A
Net margin
N/A
COGT's operating income has dropped by 70% year-on-year and by 8% since the previous quarter
The company's net income has shrunk by 63% YoY and by 6% QoQ

Growth

What is Cogent Biosciences's growth rate over time

Valuation

What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
3.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 4.5% YoY but it rose by 3.3% QoQ
The P/B is 67% above the 5-year quarterly average of 2.1 and 25% above the last 4 quarters average of 2.8
The company's equity rose by 19% YoY but it fell by 13% QoQ

Efficiency

How efficient is Cogent Biosciences business performance
The company's return on equity fell by 21% YoY and by 2.3% QoQ
COGT's return on invested capital is up by 16% since the previous quarter
The ROA has contracted by 14% YoY

Dividends

What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COGT.

Financial health

How did Cogent Biosciences financials performed over time
The total liabilities has surged by 109% year-on-year but it has declined by 12% since the previous quarter
Cogent Biosciences's total assets has increased by 27% YoY but it has decreased by 13% QoQ
The company's debt is 91% lower than its equity
The company's equity rose by 19% YoY but it fell by 13% QoQ
Cogent Biosciences's debt to equity has increased by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.